The Pharma Innovation Awards 2023 recognizes Quotient Sciences’ FlowInova platform with an award for its ability to streamline the scale-up process for early-phase API development.

Born out of a collaboration with the University of Nottingham, the FlowInova platform utilizes high-throughput experimentation and modeling. As data accumulates and process knowledge grows, predictive process models enable virtual design of experiments, ultimately enhancing the overall efficiency and effectiveness of the development process.

This significantly reduces the time and material quantities required for scale-up within a laboratory setting. This translates to accelerated drug substance API development timelines, cost savings, and greater productivity for drugmakers.

Read the feature article on Pharma Manufacturing below, and contact us for more information about how the Flowinova platform could help accelerate your API development timelines.

Read more

Quotient Sciences is one of the 2023 winners of the SME British Made Awards. The company was recognized as the Most Innovative Tailored Drug Development Company in this year's awards.

The awards are given solely on merit and are awarded to commend those most deserving for their ingenuity and hard work, distinguishing them from their competitors and proving them worthy of recognition.

We have been judged to show that we are always improving our skills and reach, contributing to elevating our industry, and ultimately enabling the UK drug development market to flourish further into the future.

Awards Coordinator Jack Ford commented: "The British Made Awards are here to celebrate those making waves in their industries not simply for the present moment, but for the near and distant future of the market in the UK."

We would like to thank all those at the SME for the recognition and this award.

Contact us about our award-winning tailored drug development services today.

Continuous flow manufacturing is taking off in the production of active pharmaceutical ingredients (APIs).

In a conversation with Outsourcing Pharma at CPHI Barcelona, Dr. Paul Quigley, former principal research fellow of drug substance at Quotient Sciences, explained how APIs are traditionally made using a method called batch manufacturing and continuous manufacturing is on the rise. 

Batch manufacturing can require hundreds of tons of raw material and the drug substance manufacturing process often takes months. Another major disadvantage of this process is that it can be difficult to perform safely and sustainably when hazardous reagents are used at high temperatures and pressures.

To overcome this obstacle, Quotient Sciences is part of a growing wave of companies exploring an alternative approach known as flow technology or continuous flow manufacturing. Flow technology has been around for centuries, the process is often used to mass-produce industrial chemicals using catalysts. This method continuously mixes reagents in tubes and requires much smaller amounts of hazardous reagents than batch processes.

Flow technology could reduce waste in the API manufacturing process and make it safer, faster, and cheaper.

In December 2022, Quotient Sciences completed the construction of a flexible, modular, kilo-scale drug substance manufacturing facility at our Quotient Sciences Alnwick site, a £6 million investment. This investment created 4 production suites, which can house a range of reactors, both continuous and batch, with the latter going up to 150 L in scale. Our Alnwick, UK, facility was perfectly placed for this expansion and it had both the available space and a wealth of local, expert scientific talent with an abundance of experience.

The impact of continuous flow manufacturing technology on the pharmaceutical industry is just beginning to be felt, and the World Economic Forum included them in its list of the 10 best new technologies of 2021.

Continue Reading

NOTTINGHAM, UK; October 24, 2023 – Quotient Sciences, the drug development and manufacturing accelerator, announced that it has made a major investment in the sterile fill/finish capabilities at its Alnwick, UK facility. This investment will increase the current capacity of the Annex 1 compliant facility to meet increasing industry demand for fully integrated drug development programs.

The company has state-of-the-art contract development and manufacturing (CDMO) facilities in both the US and UK, which are fully integrated with their clinical testing facilities in Nottingham (UK) and Miami (US) to deliver industry-leading cost and time efficiencies.

This latest investment provides a major boost to the Alnwick facility, increasing the number of Grade C cleanrooms from one to three.

As part of this expansion, the company has invested in a new isolator technology, enabling larger batch sizes and reduced cycle times per manufacturing campaign. The site also benefits from an integrated in-house microbiology team to accelerate testing and environmental monitoring, with further investment in the microbiology labs planned for next year.

Gareth Jenkins, VP Science & Technology at Quotient Sciences, said: “Navigating the development, analytical, and new Annex 1 regulatory requirements for sterile/aseptic drugs can be complicated, but with these enhancements, we have the specialized expertise and dedicated facilities to ensure successful and timely program delivery.

“With the demand for aseptic fill/finish continuing to grow across the pharmaceutical industry, and the requirements of Annex 1 that came into effect in August 2023, there is a greater global focus around regulatory requirements, commitment to quality, robust processes and containment strategies for CDMOs providing these services.

“The Alnwick site is a center of excellence for sterile product development, with ongoing recruitment and expansion of the team to ensure we meet growing market demand.”

Quotient Sciences has over 30 years of experience in the development of sterile parenteral drug products, from candidate development through to clinical trial manufacturing, including radiolabeled, high-potency, and cytotoxic compounds. The company’s flagship platform, Translational Pharmaceutics®, fully integrates drug substance, drug product, and clinical testing activities, which facilitates real-time decision-making based on emerging clinical data.  This approach provides flexibility to adjust formulations within a study, which accelerates development timelines, minimizes risk, and reduces costs.

Thierry Van Nieuwenhove, CEO of Quotient Sciences, added: "At Quotient Sciences, our mission is to help get new medicines to patients faster. Increasing our capacity for sterile fill/finish operations, investing in new technologies, and expanding our team, enables us to further support our customers with fully integrated Translational Pharmaceutics programs for sterile product development, which reduces development risks, shortens timelines, and improves the chances of success."

About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.

Quotient Sciences Company Contact
Kieron Hall
SVP & Chief Commercial Officer
(TEL) +44 7900 896428
[email protected]

An updated formulation of Medivir's fostrox, suitable for commercial manufacture, has recently been finalized through a program of work with Quotient Sciences.

Medivir AB (Nasdaq Stockholm: MVIR) is a Swedish biotech company that focuses on innovative pharmaceuticals to address unmet medical needs in oncology. Quotient Sciences has partnered with Medivir over the past several years, most recently with formulation development activities and drug product manufacturing of fostroxacitabine bralpamide (fostrox). Medivir announced that an updated formulation of fostrox that is suitable for commercial manufacture has been finalized. 

Medivir announced that an updated formulation of fostrox that is suitable for commercial manufacture has been finalized. 

Fostrox is currently under evaluation as a potential treatment for hepatocellular carcinoma (HCC), a potentially life-threatening form of liver cancer that is the third leading cause of cancer-related death worldwide. Fostrox received a positive opinion on orphan medicinal drug designation by EMA and was granted orphan drug designation by the FDA for the treatment of HCC. 

The development of an updated commercial formulation is a milestone towards fostrox becoming a treatment option for HCC patients worldwide. A Phase 1b/2a study is still ongoing to evaluate fostrox in combination with Lenvima®, a tyrosine kinase inhibitor used to treat certain kinds of cancer.

Read Medivir's announcement

Contact us for more information about how we can support your next oncology drug program.

LENVIMA® is a registered trademark by Eisai R&D Management Co., Ltd.